Metastatic prostate cancer (PCa) patients are treated with androgen deprivation therapies (ADT) to deplete systemic androgen levels and inhibit androgen binding to the androgen receptor (AR) protein in prostate cancer (PCa) cells [1]. The gene discussed is AR; the disease is prostate carcinoma.